Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of BK6501 in healthy Japanese adults aged 60 years or older
jRCT2051250215Phase 2Completed
- Sponsor
- Research Foundation for Microbial Diseases of Osaka University
- Start
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of BK6501 and ARCT-2138 in influenza (2 arms), sponsored by Research Foundation for Microbial Diseases of Osaka University. Primary endpoints: Solicited injection site reactions, Solicited systemic reactions and 6 more. Started Feb 2026; status: completed.
02
Drugs
BK6501ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2051250215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250215.